Snowstorm Dashes Hopes for Sarepta Drug's Dystrophy Patients

  • FDA hearing on controversial drug delayed by bad weather
  • `Devastating,' says father who traveled to D.C. with sick son

Dozens of doctors and families who flew to Washington with sick children to try to convince regulators to approve Sarepta Therapeutics Inc.’s experimental drug for a deadly disease are left at loose ends, their hopes on hold after a review was delayed due to the approaching snowstorm.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.